Bulk Manufacturer of Controlled Substances Application: Invizyne Technologies, Inc., 7173-7174 [2025-01347]

Download as PDF 7173 Federal Register / Vol. 90, No. 12 / Tuesday, January 21, 2025 / Notices substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DEPARTMENT OF JUSTICE Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2025. Such persons may also file a written request for a hearing on the application on or before March 24, 2025. [Docket No. DEA–1477] The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. ADDRESSES: In accordance with 21 CFR 1301.33(a), this is notice that on September 27, 2024, Groff Health Inc., 2218 South Queen Street, York, Pennsylvania 17402–4631 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): SUPPLEMENTARY INFORMATION: Psilocybin ....................... Psilocyn .......................... I Drug code Schedule 7437 7438 I I I The company plans to bulk manufacture the listed controlled substances for internal use or for sale to its customers. No other activities for these drug codes are authorized for this registration. ddrumheller on DSK120RN23PROD with NOTICES1 Matthew Strait, Deputy Assistant Administrator. [FR Doc. 2025–01349 Filed 1–17–25; 8:45 am] BILLING CODE P VerDate Sep<11>2014 19:56 Jan 18, 2025 Jkt 265001 Drug code Schedule 9050 9143 9150 9193 9250 9254 9300 9330 9333 9630 9652 9780 II II II II II II II II II II II II Drug Enforcement Administration DATES: Controlled substance Controlled substance Bulk Manufacturer of Controlled Substances Application: Siegfried USA, LLC Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Siegfried USA, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2025. Such persons may also file a written request for a hearing on the application on or before March 24, 2025. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on November 20, 2024, Siegfried USA, LLC, 33 Industrial Park Road, Pennsville, New Jersey 08070– 3244 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): SUMMARY: Controlled substance Gamma Hydroxybutyric Acid. Dihydromorphine ............ Hydromorphinol .............. Amphetamine ................. Lisdexamfetamine .......... Methylphenidate ............. Amobarbital .................... Pentobarbital .................. Secobarbital .................... PO 00000 Frm 00103 Fmt 4703 Drug code Schedule 2010 I 9145 9301 1100 1205 1724 2125 2270 2315 I I II II II II II II Sfmt 4703 Codeine .......................... Oxycodone ..................... Hydromorphone .............. Hydrocodone .................. Methadone ...................... Methadone intermediate Morphine ......................... Oripavine ........................ Thebaine ......................... Opium tincture ................ Oxymorphone ................. Tapentadol ...................... The company plans to bulk manufacture the listed controlled substances in bulk for sale to its customers. No other activities for these drug codes are authorized for this registration. Matthew Strait, Deputy Assistant Administrator. [FR Doc. 2025–01350 Filed 1–17–25; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–1474] Bulk Manufacturer of Controlled Substances Application: Invizyne Technologies, Inc. Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Invizyne Technologies, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2025. Such persons may also file a written request for a hearing on the application on or before March 24, 2025. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be SUMMARY: E:\FR\FM\21JAN1.SGM 21JAN1 7174 Federal Register / Vol. 90, No. 12 / Tuesday, January 21, 2025 / Notices aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on November 14, 2024, Invizyne Technologies, Inc., 750 Royal Oaks Drive, Suite 106, Monrovia, California 91016–6357 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled substance Drug code Schedule 7370 I Tetrahydrocannabinols ... The company plans to bulk manufacture the listed controlled substance for the internal use intermediates or for sale to its customers. In reference to drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture this drug as synthetic. No other activity for this drug code is authorized for this registration. Matthew Strait, Deputy Assistant Administrator. [FR Doc. 2025–01347 Filed 1–17–25; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE National Institute of Justice [OJP (NIJ) Docket No. 1833] Body Armor Manufacturer Workshop National Institute of Justice, Office of Justice Programs, U.S. Department of Justice. ACTION: Notice. AGENCY: The National Institute of Justice (NIJ) will hold an online workshop for body armor manufacturers to provide updates on its standards and conformity assessment activities related to ballistic-resistant body armor. DATES: The workshop will be held online Wednesday, March 19, 2025, from 1 p.m. to 3 p.m. eastern time. FOR FURTHER INFORMATION CONTACT: Jared Gardner, Technology and Standards Advisor, Office of Technology and Standards, National Institute of Justice, 999 North Capitol Street NE, Washington, DC 20531, by telephone at (202) 702–2917 [Note: this is not a toll-free telephone number], or by email at jared.gardner@usdoj.gov. ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 19:56 Jan 18, 2025 Jkt 265001 The National Institute of Justice (NIJ) will hold an online workshop for body armor manufacturers to provide updates on its standards and conformity assessment activities related to ballistic-resistant body armor. NIJ will discuss recent addenda to NIJ Standard 0101.07, ‘‘Ballistic Resistance of Body Armor’’, and NIJ Standard 0123.00, ‘‘Specification for NIJ Ballistic Protection Levels and Associated Test Threats’’. The NIJ Compliance Testing Program (CTP) will update program participants on the initial implementation of testing body armor to NIJ Standard 0101.07 (‘‘07’’) and the anticipated timeline for publication of the NIJ Compliant Products List (CPL) for those ‘‘07’’ armor models. The NIJ CTP will also discuss ongoing administration of the NIJ CPL for armor compliant with NIJ Standard 0101.06 (‘‘06’’) and continued Follow-up Inspection and Testing (FIT) for those ‘‘06’’ armor models. Potential revisions to NIJ CTP program requirements will also be discussed, including FIT testing procedures for ‘‘07’’ armor models listed on the NIJ CPL, disclosure of information about ballistic materials used to manufacture body armor submitted to the NIJ CTP for certification, and labeling requirements, among others. NIJ will also discuss potential changes to how information is displayed on the NIJ Compliant Products List and how it anticipates future updates to NIJ standards and NIJ CTP program requirements will be communicated. The workshop will be presented as an online webinar with opportunities for attendees to ask questions. To register for the workshop, please send an email to askctp@nijctp.org by 5 p.m. eastern time on Friday, March 14, 2025, and provide the name of your company and the names of the representatives who will attend. Please put ‘‘Body Armor Manufacturer Workshop’’ in the subject line of the email. A preliminary agenda will be sent to registered attendees approximately 48 hours prior to the workshop. For more information on NIJ’s standards and conformity assessment activities, please visit https:// nij.ojp.gov/topics/equipment-andtechnology/standards-and-conformityassessment. For more information on body armor, please visit https:// nij.ojp.gov/topics/equipment-andtechnology/body-armor. More information on the NIJ CTP can be found here: https://cjttec.org/ compliance-testing-program/. SUPPLEMENTARY INFORMATION: PO 00000 Frm 00104 Fmt 4703 Sfmt 4703 NIJ publishes this notice pursuant to its authority at 34 U.S.C. 10122(c) and 6 U.S.C. 161–165. Nancy La Vigne, Director, National Institute of Justice. [FR Doc. 2025–01247 Filed 1–17–25; 8:45 am] BILLING CODE 4410–18–P DEPARTMENT OF LABOR Employee Benefits Security Administration [Exemption Application No. D–12101] Proposed Exemption From Certain Prohibited Transaction Restrictions Involving Northern Trust Corporation (Together With its Current and Future Affiliates, Northern or the Applicant) Located in Chicago, IL Employee Benefits Security Administration, Labor. ACTION: Notice of proposed exemption. AGENCY: This document provides notice of the pendency before the Department of Labor (the Department) of a proposed individual exemption from certain prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974 (ERISA) and the Internal Revenue Code of 1986 (the Code). The proposed exemption would allow certain entities with specified relationships to Northern Trust Fiduciary Services (Guernsey) Limited (NTFS) (hereinafter, the Northern QPAMs, as further defined in section I(e) of the operative language) to rely on the exemptive relief provided by Prohibited Transaction Class Exemption 84–14 (PTE 84–14 or the QPAM Exemption), notwithstanding the judgment of conviction (the Conviction) against NTFS for aiding and abetting tax fraud entered in France in the Paris Court of Appeal, French Special Prosecutor No. 1120392066, French Investigative Judge No. JIRSIF/11/12. DATES: Exemption date: This proposed exemption would be in effect for a period of five years beginning on March 5, 2025, and ending on March 4, 2030 (the Exemption Period). Comments due: Written comments and requests for a public hearing on the proposed exemption should be submitted to the Department by March 7, 2025. ADDRESSES: All written comments and requests for a hearing should be submitted to the Employee Benefits Security Administration (EBSA), Office of Exemption Determinations, Attention: Application No. D–12101 via SUMMARY: E:\FR\FM\21JAN1.SGM 21JAN1

Agencies

[Federal Register Volume 90, Number 12 (Tuesday, January 21, 2025)]
[Notices]
[Pages 7173-7174]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-01347]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1474]


Bulk Manufacturer of Controlled Substances Application: Invizyne 
Technologies, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Invizyne Technologies, Inc. has applied to be registered as a 
bulk manufacturer of basic class(es) of controlled substance(s). Refer 
to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants, therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
March 24, 2025. Such persons may also file a written request for a 
hearing on the application on or before March 24, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be

[[Page 7174]]

aware that submitted comments are not instantaneously available for 
public view on https://www.regulations.gov. If you have received a 
Comment Tracking Number, your comment has been successfully submitted 
and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on November 14, 2024, Invizyne Technologies, Inc., 750 
Royal Oaks Drive, Suite 106, Monrovia, California 91016-6357 applied to 
be registered as a bulk manufacturer of the following basic class(es) 
of controlled substance(s):

------------------------------------------------------------------------
                                          Drug
          Controlled substance            code           Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols..................    7370  I
------------------------------------------------------------------------

    The company plans to bulk manufacture the listed controlled 
substance for the internal use intermediates or for sale to its 
customers. In reference to drug code 7370 (Tetrahydrocannabinols), the 
company plans to bulk manufacture this drug as synthetic. No other 
activity for this drug code is authorized for this registration.

Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025-01347 Filed 1-17-25; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.